Advertisement

The Use of Monoclonal Antibodies in Clinical Transplantation

  • G. Opelz
Chapter
Part of the Developments in Hematology and Immunology book series (DIHI, volume 10)

Abstract

With the introduction of monoclonal antibodies by Köhler and Milstein (1), both basic and clinical immunology have moved into a new era of fascinating new opportunities. Thus far, the basic scientists have been the primary beneficiaries. Antibodies of absolute purity and specificity allow the in vitro characterization of, and interaction with, specific molecules of the immunologically reactive cell. The antibodies are of such delicate specificity that different monoclonal antibodies can react with different epitopes of the same molecule, without steric hindrance. The in vivo application in experimental animals provided new insights into various immuno-regulatory mechanisms. Clinical medicine is beginning to utilize monoclonal antibodies as a diagnositc tool and, in first carefully controlled studies, the feasibility of their therapeutic use is being explored.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Köler G, Milstein C. Continous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495–7.CrossRefGoogle Scholar
  2. 2.
    Foster CS. Lymphocyte hybridmas. Cancer Treat Rev 1982; 9: 59–84.PubMedCrossRefGoogle Scholar
  3. 3.
    Sharp TG, Sachs DH, Fauci AS, Messerschmidt GL, Rosenberg SA. T cell depletion of human bone marrow using monoclonal antibody and complement-mediated lysis. Transplantation 1983; 35: 112–20.PubMedCrossRefGoogle Scholar
  4. 4.
    Friedrich W, O’Reilly RJ, Koziner B, Gebhard DF, Good RA, Evans RL. T-lymphocyte reconstitution in recipients of bone marrow transplants with and without GvHD. Blood 1982; 59: 696–701.PubMedGoogle Scholar
  5. 5.
    Atkinson K, Hansen JA, Storb R, Goehle S, Goldstein G, Thomas ED. T-cell subpopulations identified by monoclonal antibodies after human bone marrow transplantation. Blood 1982; 59: 1292–8.PubMedGoogle Scholar
  6. 6.
    Fox R, McMillan R, Spruce W, et al. Analysis of T lymphocytes after bone marrow transplantation using monoclonal antibodies. Blood 1982; 60: 578–82.PubMedGoogle Scholar
  7. 7.
    Schroff RW, Gale RP, Fahey JL. Regeneration of T cell subpopulations after bone marrow transplantation. J Immunol 1982; 129: 1926–30.PubMedGoogle Scholar
  8. 8.
    Martin PJ, Shulman HM, Schubach WH, et al. Fatal EBV-associated proliferation of donor B cells following treatment of acute graft-versus-host disease with a murine monoclonal anti-T cell antibody. N Engl J Med (in press).Google Scholar
  9. 9.
    Müller-Ruchholtz W, Wottge HU, Müller-Hermelink HK. Bone marrow transplantation in rats across strong histocompatibility barriers by selective elimination of lymphoid cells in donor marrow. Transplant Proc 1976; 8: 537–40.PubMedGoogle Scholar
  10. 10.
    Thierfelder S, Hoffmann-Fezer G, Rodt H, Doxiadis I, Eulitz M, Kummer U. Antilymphocytic antibodies in marrow transplantation. Transplantation 1983; 35: 249–54.PubMedCrossRefGoogle Scholar
  11. 11.
    Vallera DA, Soderling CCB, Kersey JH. Bone marrow transplantation across major histocompatibility barriers in mice. J Immunol 1982; 128: 871–5.PubMedGoogle Scholar
  12. 12.
    Prentice HG, Blacklock HA, Janossy G, et al. Use of anti-T-cell monoclonal antibody 0KT3 to prevent acute graft-versus-host disease in allogeneic bone-marrow transplantation for acute leukaemia. Lancet 1982;i:700–3.CrossRefGoogle Scholar
  13. 13.
    Filipovich A, McGlave PB, Ramsay NK, Goldstein G, Warkentin PI, Kersey JH. Pretreatment of donor bone marrow with monoclonal antibody 0KT3 for prevention of acute graft-versus-host disease in allogeneic histocompatible bone-marrow transplantation. Lancet 1982;i: 1266–9.CrossRefGoogle Scholar
  14. 14.
    Hayward AR, Murphy S, Githens J, Troup G, Ambruso D. Failure of a pan-reactive anti-T cell antibody, 0KT3, to prevent graft versus host disease in severe combined immunodeficiency. J Pediatr 1982; 100: 665–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Medical News. Mismatches marrow grafts succeed thanks to two anti-T-cell agents. JAMA 1983; 249: 1687–9.CrossRefGoogle Scholar
  16. 16.
    Ritz J, Sallan SE, Bast RC, et al. Autologous bone-marrow transplantation in CALLA-positive acute lymphoblastic leukaemia after in-vitro treatment with J5 monoclonal antibody and complement. Lancet 1982;ii:60–3.CrossRefGoogle Scholar
  17. 17.
    Cosimi AB, Colvin RB, Burton RC, et al. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med 1981; 305: 308–14.PubMedCrossRefGoogle Scholar
  18. 18.
    Ellis TM, Lee HM, Mohanakumar T. Alterations in human regulatory T lymphocyte subpopulations after renal allografting. J Immunol 1981; 127: 2199–203.PubMedGoogle Scholar
  19. 19.
    Mazaheri R, Laupacis A, Keown P, Howson W, Sinclair NR, Stiller CR. Lymphocyte subsets in the allograft recipient. Transplant Proc 1982; 14: 676–8.PubMedGoogle Scholar
  20. 20.
    Nanni-Costa A, Vangelista A, Frasca GM, Stefoni S, Bonomini V. T-cell subsets in renal allograft recipients. Transplant Proc 1983; 15: 1176–7.Google Scholar
  21. 21.
    Binkley WF, Valenzuela R, Braun WE, Deodhar SD, Novick AC, Steinmuller DR. Flow cytometry quantitation of peripheral blood T-cell subsets in human renal allograft recipients. Transplant Proc 1983; 15: 1163–5.Google Scholar
  22. 22.
    Carter NP, Cullen PR, Thompson JF, Bewick ALT, Wood RFM, Morris PJ. Monitoring lymphocyte subpopulations in renal allograft recipients. Transplant Proc 1983; 15: 1157–9.Google Scholar
  23. 23.
    Guttmann RD, Poulsen RS. Fluorescence activated cell sorter analysis of lymphocyte subsets after renal transplantation. Transplant Proc 1983; 15: 1160–2.Google Scholar
  24. 24.
    Chatenoud L, Chkoff N, Kreis H, Bach JF. Interest in and limitations of monoclonal anti-T-cell antibodies for the follow-up of renal transplant patients. Transplantation 1983; 36: 45–50.PubMedCrossRefGoogle Scholar
  25. 25.
    Daniel V, Opelz G. Lymphocyte subset monitoring in renal transplant recipients. Transplant Proc (in press).Google Scholar
  26. 26.
    Colvin RB, Cosimi AB, Burton RC, et al. Circulating T-cell subsets in 72 human renal allograft recipients. Transplant Proc 1983; 15: 1166–9.Google Scholar
  27. 27.
    Piatt FL, LeBien TW, Michael AF. Interstitial mononuclear cell populations in renal graft rejection. J Exp Med 1982; 155: 17–30.CrossRefGoogle Scholar
  28. 28.
    De Waele M, Thielemans C, Van Camp BKG. Characterization of immunoregulatory T cells in EBV-induced infectious mononucleosis by monoclonal antibodies. N Engl J Med 1981; 304: 460–2.PubMedCrossRefGoogle Scholar
  29. 29.
    Schooley RT, Hirsch MS, Colvin RB, et al. Association of herpesvirus infection with T-lymphocyte subset alterations, glomerulopathy, and opportunistic infections after renal transplantation. N Engl J Med 1983; 308: 307–13.PubMedCrossRefGoogle Scholar
  30. 30.
    Cosimi AB, Burton RC, Colvin RB, et al. Treatment of acute renal allograft rejection with 0KT3 monoclonal antibody. Transplantation 1981; 32: 535–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Bach JF, Dardenne M, Chatenoud L. Immunomodulation of T cells by thymic hormone and monoclonal anti-T cell antibody. Transplant Proc 1982; 14: 509–12.PubMedGoogle Scholar
  32. 32.
    Chatenoud L, Baudrihaye MF, Chkoff N, Kreis H, Bach JF. Immunologic follow-up of renal allograft recipients treated prophylactically by 0KT3 alone. Transplant Proc 1983; 15: 643–5.Google Scholar
  33. 33.
    Takahashi H, Okazaki H, Terasaki PI, et al. Reversal of transplant rejection by monoclonal antiblast antibody. Lancet 1983;ii:1155–8.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1984

Authors and Affiliations

  • G. Opelz

There are no affiliations available

Personalised recommendations